Ophthalmology

New cross-sectional research indicates factors influencing ocular lesion status can include diabetes status, prednisolone dosage, and systemic infection status after kidney transplantation.

Results from the phase 3 NEAR-1 and NEAR-2 clinical trials show consistent efficacy and tolerability of the preservative-free, low-dose eye drop in patients with presbyopia.

A recent nationwide cohort study identified statistically significant associations between IBD and DED, as well as increased risks of corneal surface damage.

An analysis of 14 studies revealed that uveitis had an estimated prevalence of 3.27% in Crohn's disease and 1.60% in ulcerative colitis.

Adolescents from socioeconomically disadvantaged backgrounds were less likely to report receiving a vision test, particularly in clinical settings.

In a 12-month, real-world study, the implant was effective in more than half of eyes with non-infectious uveitis, achieving effectiveness as soon as 2 weeks post-implantation.

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.

The latest episode of our mini-docuseries focuses on disparities in ophthalmology, from preventable vision impairment to gaps in access in underserved communities.

Our ophthalmology month in review for September 2023 highlights our top stories in retina, the latest news from the FDA, and insights into the evolving specialty landscape.

The technology could be an important step toward point-of-care diagnostics for microbial keratitis in primary care or other healthcare settings without a laboratory.

Overall quality of life appeared good during the COVID-19 pandemic, but the presence of retinal disease and the number of nonocular comorbidities were linked to negative impacts on vision-related quality of life.

According to the approval, the percentage of study eyes returning to ≤0.2 mm from baseline pupil diameter was statistically significantly greater in the phentolamine ophthalmic solution group than placebo.

Smartphone measurements were found to be accurate and precise compared with Hertel exophthalmometry or a high-resolution scanner.

The systematic review and meta-analysis of 13 studies found no evidence to support the use of topical NSAIDs for the treatment of central serous chorioretinopathy.

The analysis of questionnaire responses in Sweden suggests the socioeconomic factor of low household income had a crucial impact on vision-related quality of life.

Artificial intelligence use is growing across medicine. From imaging to chatbots, ophthalmology is the center of one of these transformations.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

On September 12, 2023, the FDA announced it had issued warning letters to 8 companies, including CVS Health and Walgreens, for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law.

A cross-sectional analysis of Medicare Part B data spending shows ophthalmologists who received manufacturer funding were less likely to prescribe bevacizumab.

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and managing director of Opthea Limited, to discuss sozinibercept, a novel recombinant “trap” fusion protein targeting inhibition of VEGF-C and VEGF-D.

Analyses suggest users of calcium channel blockers had 39% higher odds of glaucoma compared with non-users, after controlling for confounders.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

An analysis of ophthalmology subspecialty fellowships in 2021 revealed a lower match rate for applicants considered underrepresented in medicine.

Outlook Therapeutics announced receipt of the CRL exactly one year after resubmission of their BLA for ONS-5010 as a treatment for wet age-related macular degeneration, which would have been the first indication for a retinal disease given to an ophthalmic version of bevacizumab.

Experts wrap up their discussion by highlighting key takeaways on the treatment of retinal diseases with anti-vascular endothelial growth factor (Anti-VEGF) therapies.

Experts discuss emerging gene therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) and key end points considerations.

Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.

The adjusted odds of vision testing decreased by 41% for uninsured and 24% for publicly insured participants versus those with private insurance.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.